Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis
Anindita Bhoumik, Tian-Gui Huang, Vladimir Ivanov, Lisa Gangi, Rui F. Qiao, Savio L.C. Woo, Shu-Hsia Chen, Ze’ev Ronai
Anindita Bhoumik, Tian-Gui Huang, Vladimir Ivanov, Lisa Gangi, Rui F. Qiao, Savio L.C. Woo, Shu-Hsia Chen, Ze’ev Ronai
View: Text | PDF
Article Oncology

An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis

  • Text
  • PDF
Abstract

Research Article

Authors

Anindita Bhoumik, Tian-Gui Huang, Vladimir Ivanov, Lisa Gangi, Rui F. Qiao, Savio L.C. Woo, Shu-Hsia Chen, Ze’ev Ronai

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Intratumoral injection of adenovirus bearing the ATF2 peptide causes red...
Intratumoral injection of adenovirus bearing the ATF2 peptide causes reduction of growth as well as complete regression of B16F10 tumors. C57BL/6 mice were injected with B16F10 cells, and tumors grew before injections of adenovirus bearing the ATF2 or control construct were initiated. Virus injection took place at the time points indicated in c (green arrows). (a) Representative tumors developed under each of the protocols. (b) The ATF2 peptide inhibited metastasis of the tumors. Green arrows point to metastatic lesions in the lungs seen in the control but not the treatment group; the black area in the photograph of ATF2 peptide–expressing mice depicts the heart. (c) Overall changes in the growth rate of the tumors subjected to control or ATF2 peptide treatments (compiled from the two experiments). Comparisons between all experimental groups are significant (P < 0.0001) as calculated by Tukey’s multiple comparisons (Tukey’s honestly significant difference). (d) The effect of ATF2 peptide on the survival of the mice under each of the protocols used.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts